MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...
A 24-week telehealth program combining long-acting anti-obesity medications (AOMs) with tailored virtual behavioral support lead to meaningful weight loss and blood pressure reductions among ...
Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain most - but ...
A meta-analysis involving more than 43,000 adults with obesity, suggests that obesity medications, such as GLP-1 drugs, could ...
The study population saw noted payoff when they paired this trending apparel with another crucial activity.